Novel Concepts for Intrauterine Device Placement at Caesarean Delivery: Description of Technique and Video Recording by G. Justus Hofmeyr, Kyungu M. Kime

“…The International Federation of Gynaecology and Obstetrics recommend digital insertion of the copper intrauterine device (IUD) during caesarean delivery and note the risk of thread inclusion in the uterotomy closure and nonvisibility of threads at follow-up. …”
Get full text

Transcervical resection of myoma (TCRM): Part II by Peng-Hui Wang, Szu-Ting Yang, Wen-Hsun Chang, Hung-Hsien Liu, Wen-Ling Lee

“…In the part I, we have already reported the rationale, efficacy, complication, and limitation of using transcervical resection of myoma (TCRM) in the management of women with symptomatic uterine fibroids, particularly for those belonging to the International Federation of Gynaecology & Obstetrics (FIGO) myoma classification system as FIGO types 0–2. …”
Get full text

The differential expression of AFF3 in cervical cancer and its correlation with clinicopathological features and prognosis by Yaxuan Zhang, Lanying Li, Qingling Han, Lanying Wen

“…The Univariate analysis of prognostic risk factors was conducted using the COX proportional hazards model, followed by multivariate COX regression analysis including variables with p < 0.01.Results AFF3 expression was downregulated in CC, and its levels were correlated with lymph node metastasis (LNM) and International Federation of Gynaecology and Obstetrics (FIGO) stage. Patients with low AFF3 expression had a lower 5-year OS rate (52.78%, 19/36). …”
Get full text

Transcervical resection of myoma (TCRM): Part I by Peng-Hui Wang, Szu-Ting Yang, Wen-Hsun Chang, Hung-Hsien Liu, Wen-Ling Lee

“…However, to offer a practical standardized consensus for the description and categorization of myomas, the International Federation of Gynaecology &amp; Obstetrics (FIGO) classification system from type 0 to type 8 is established, which is often used for guiding patient management and offering prognostic information, because submucosal myoma (FIGO type 0, 1, probable 2, and possible 3) is frequently associated with symptoms or signs, needing a further intervention. …”
Get full text

Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-labe... by Ying Zhu, Jianwei Zhou, Zhigang Zhang, Jiaojiao Zhang, Jing Fei, Xiaoqing Zhu

“…The NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr(NAIVE) study aims to assess the clinical efficacy and safety of NACT in combination with tislelizumab (a monoclonal antibody for programmed cell death protein 1) for advanced EOC.Methods and analysis The NAIVE study is an investigator-initiated, prospective, single-centre, open-label, randomised controlled trial for advanced EOC with the International Federation of Gynaecology and Obstetrics (FIGO) stage IIIc with a Suidan CT score of 3 or greater or a Fagotti laparoscopic score of 8 or greater; or FIGO stage IV. …”
Get full text

Prognostic and diagnostic value of circRNA expression in cervical cancer: a meta analysis by Yi Xu, Yi Xu, Changxia Li, Changxia Li, Lifang Cheng, Shaoheng Wang, Yuqing Wu, Shiyang Li, Mingqiang Liu, Xiaohua Tao

“…Elevated expression levels of oncogenic circRNAs were significantly associated with poor clinical indicators, including tumour size (odds ratio [OR] = 0.425, 95% confidence interval [CI]: 0.267–0.676), International Federation of Gynaecology and Obstetrics (FIGO) stage (OR = 0.315, 95% CI: 0.224–0.443), and lymph node metastasis (OR = 2.975, 95% CI: 1.816–4.872). …”
Get full text